PL1912673T3 - Sposób przyłączania cząsteczek efektorowych do białek - Google Patents
Sposób przyłączania cząsteczek efektorowych do białekInfo
- Publication number
- PL1912673T3 PL1912673T3 PL06744294T PL06744294T PL1912673T3 PL 1912673 T3 PL1912673 T3 PL 1912673T3 PL 06744294 T PL06744294 T PL 06744294T PL 06744294 T PL06744294 T PL 06744294T PL 1912673 T3 PL1912673 T3 PL 1912673T3
- Authority
- PL
- Poland
- Prior art keywords
- protein
- effector molecules
- proteins
- attaching
- cysteines
- Prior art date
Links
- 102000004169 proteins and genes Human genes 0.000 title abstract 5
- 108090000623 proteins and genes Proteins 0.000 title abstract 5
- 239000012636 effector Substances 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 2
- 235000018102 proteins Nutrition 0.000 abstract 4
- 239000003638 chemical reducing agent Substances 0.000 abstract 2
- 235000018417 cysteine Nutrition 0.000 abstract 2
- 150000001945 cysteines Chemical class 0.000 abstract 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 238000011026 diafiltration Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Catalysts (AREA)
- Bakery Products And Manufacturing Methods Therefor (AREA)
- Jellies, Jams, And Syrups (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0513852.4A GB0513852D0 (en) | 2005-07-06 | 2005-07-06 | Biological products |
| PCT/GB2006/002416 WO2007003898A1 (en) | 2005-07-06 | 2006-06-29 | Process for attaching effector molecules to proteins |
| EP06744294A EP1912673B1 (en) | 2005-07-06 | 2006-06-29 | Process for attaching effector molecules to proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL1912673T3 true PL1912673T3 (pl) | 2011-07-29 |
Family
ID=34856761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL06744294T PL1912673T3 (pl) | 2005-07-06 | 2006-06-29 | Sposób przyłączania cząsteczek efektorowych do białek |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8378073B2 (pl) |
| EP (1) | EP1912673B1 (pl) |
| JP (1) | JP5203188B2 (pl) |
| CN (1) | CN101212984B (pl) |
| AT (1) | ATE502650T1 (pl) |
| AU (1) | AU2006264684B2 (pl) |
| CA (1) | CA2613481C (pl) |
| DE (1) | DE602006020878D1 (pl) |
| DK (1) | DK1912673T3 (pl) |
| ES (1) | ES2361096T3 (pl) |
| GB (1) | GB0513852D0 (pl) |
| PL (1) | PL1912673T3 (pl) |
| PT (1) | PT1912673E (pl) |
| SI (1) | SI1912673T1 (pl) |
| WO (1) | WO2007003898A1 (pl) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0907046A2 (pt) * | 2008-01-18 | 2015-07-28 | Medimmune Llc | Anticorpo de cisteína engenheirada, ácido nucleico isolado, vetor, célula hospedeira, conjugado de anticorpo, composição farmacêutica, métodos de detecção de câncer, doenças ou distúrbios autoimunes, inflamatórios ou infecciosos em um indivíduo e de inibição de proliferação de uma célula alvo |
| NZ594315A (en) | 2009-02-17 | 2013-05-31 | Ucb Pharma Sa | Antibody molecules having specificity for human ox40 |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| GB0920127D0 (en) * | 2009-11-17 | 2009-12-30 | Ucb Pharma Sa | Antibodies |
| JP6106666B2 (ja) | 2011-07-07 | 2017-04-05 | ノボ・ノルデイスク・エー／エス | アドオン式の投薬取得／表示モジュールを備える薬剤送出注射ペン |
| JP2015502397A (ja) | 2011-12-23 | 2015-01-22 | ファイザー・インク | 部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用 |
| EP3079722B1 (en) * | 2013-12-13 | 2021-03-24 | Novo Nordisk Health Care AG | Method for thioether conjugation of proteins |
| KR20230088389A (ko) * | 2014-02-11 | 2023-06-19 | 씨젠 인크. | 단백질의 선택적 환원 |
| GB201419184D0 (en) * | 2014-10-28 | 2014-12-10 | Adc Biotechnology Ltd | Method of synthesising biomolecule-effector/reporter-conjugates using affinity resins |
| US20160151511A1 (en) | 2014-12-02 | 2016-06-02 | Antriabio, Inc. | Proteins and protein conjugates with increased hydrophobicity |
| AR103172A1 (es) | 2014-12-22 | 2017-04-19 | Novartis Ag | Reducción selectiva de residuos de cisteina en anticuerpos il-17 |
| CN107108691B (zh) | 2014-12-22 | 2021-06-29 | Ucb生物制药私人有限公司 | 蛋白质制造方法 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| WO2016196017A1 (en) | 2015-06-04 | 2016-12-08 | Antriabio, Inc. | Amine pegylation methods for the preparation of site-specific protein conjugates |
| WO2018119142A1 (en) | 2016-12-21 | 2018-06-28 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| JP7148524B2 (ja) * | 2017-02-08 | 2022-10-05 | ファイザー・インク | キャップされたおよびキャップされていない抗体システインのための大規模産生プロセス、ならびに治療的タンパク質コンジュゲーションにおけるその使用 |
| US11364303B2 (en) | 2017-09-29 | 2022-06-21 | Pfizer Inc. | Cysteine engineered antibody drug conjugates |
| AU2019240758B2 (en) * | 2018-03-28 | 2024-12-12 | Two-Tag Holdings Pty Ltd | Methods for measuring relative oxidation levels of a protein |
| GB201919062D0 (en) | 2019-12-20 | 2020-02-05 | Ucb Biopharma Sprl | Antibody |
| AR124250A1 (es) | 2020-12-07 | 2023-03-01 | UCB Biopharma SRL | Anticuerpos |
| PE20231953A1 (es) | 2020-12-07 | 2023-12-06 | UCB Biopharma SRL | Anticuerpos multiespecificos y combinaciones de anticuerpos |
| IL308100A (en) | 2021-05-03 | 2023-12-01 | UCB Biopharma SRL | Antibodies |
| GB202111905D0 (en) | 2021-08-19 | 2021-10-06 | UCB Biopharma SRL | Antibodies |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4728430A (en) * | 1986-02-10 | 1988-03-01 | Millipore Corporation | Diafiltration method |
| US5216183A (en) * | 1988-04-19 | 1993-06-01 | Teijin Limited | Cyclopentanone/cyclopentenone derivative |
| US5225194A (en) * | 1989-11-13 | 1993-07-06 | Ldc Research Corporation | Aqueous diafiltration process for preparing acellular vaccines, against selected bacterial diseases |
| AU1140495A (en) * | 1994-01-27 | 1995-08-03 | Bristol-Myers Squibb Company | Method for preparing thioether conjugates |
| GB9625640D0 (en) * | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| US20040121415A1 (en) * | 1996-12-10 | 2004-06-24 | King David John | Monovalent antibody fragments |
| DE19911329A1 (de) * | 1998-03-27 | 2000-09-21 | Benes Ivan Friedrich | Humantherapeutisch anwendbares Radioimmunkonjugat und Verfahren zu seiner Herstellung |
| GB9812545D0 (en) * | 1998-06-10 | 1998-08-05 | Celltech Therapeutics Ltd | Biological products |
| WO2000025902A1 (en) * | 1998-10-30 | 2000-05-11 | Nephros, Inc. | Non-isosmotic diafiltration system |
| US6146902A (en) * | 1998-12-29 | 2000-11-14 | Aventis Pasteur, Inc. | Purification of polysaccharide-protein conjugate vaccines by ultrafiltration with ammonium sulfate solutions |
| US6406631B1 (en) * | 1999-07-30 | 2002-06-18 | Nephros, Inc. | Two stage diafiltration method and apparatus |
| GB0303337D0 (en) * | 2003-02-13 | 2003-03-19 | Celltech R&D Ltd | Biological products |
| CN1621091A (zh) * | 2003-11-28 | 2005-06-01 | 付经国 | 聚乙二醇化轮状病毒体肠靶向制剂及其合成方法 |
| GB0425569D0 (en) * | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| US7908694B1 (en) * | 2008-09-24 | 2011-03-22 | Robert Sloane | Mattress cover apparatus with integrated seals |
-
2005
- 2005-07-06 GB GBGB0513852.4A patent/GB0513852D0/en not_active Ceased
-
2006
- 2006-06-29 PL PL06744294T patent/PL1912673T3/pl unknown
- 2006-06-29 JP JP2008518969A patent/JP5203188B2/ja active Active
- 2006-06-29 EP EP06744294A patent/EP1912673B1/en active Active
- 2006-06-29 AU AU2006264684A patent/AU2006264684B2/en active Active
- 2006-06-29 CA CA2613481A patent/CA2613481C/en active Active
- 2006-06-29 ES ES06744294T patent/ES2361096T3/es active Active
- 2006-06-29 DE DE602006020878T patent/DE602006020878D1/de active Active
- 2006-06-29 SI SI200631002T patent/SI1912673T1/sl unknown
- 2006-06-29 PT PT06744294T patent/PT1912673E/pt unknown
- 2006-06-29 US US11/994,053 patent/US8378073B2/en active Active
- 2006-06-29 CN CN2006800234116A patent/CN101212984B/zh active Active
- 2006-06-29 WO PCT/GB2006/002416 patent/WO2007003898A1/en not_active Ceased
- 2006-06-29 DK DK06744294.7T patent/DK1912673T3/da active
- 2006-06-29 AT AT06744294T patent/ATE502650T1/de active
Also Published As
| Publication number | Publication date |
|---|---|
| US20080306246A1 (en) | 2008-12-11 |
| PT1912673E (pt) | 2011-04-14 |
| CN101212984B (zh) | 2011-09-28 |
| ES2361096T3 (es) | 2011-06-13 |
| AU2006264684B2 (en) | 2011-11-03 |
| DK1912673T3 (da) | 2011-05-02 |
| GB0513852D0 (en) | 2005-08-10 |
| ATE502650T1 (de) | 2011-04-15 |
| CA2613481C (en) | 2014-11-25 |
| US8378073B2 (en) | 2013-02-19 |
| CN101212984A (zh) | 2008-07-02 |
| SI1912673T1 (sl) | 2011-10-28 |
| AU2006264684A1 (en) | 2007-01-11 |
| JP5203188B2 (ja) | 2013-06-05 |
| EP1912673A1 (en) | 2008-04-23 |
| WO2007003898A8 (en) | 2008-10-09 |
| JP2008544976A (ja) | 2008-12-11 |
| DE602006020878D1 (de) | 2011-05-05 |
| WO2007003898A1 (en) | 2007-01-11 |
| CA2613481A1 (en) | 2007-01-11 |
| EP1912673B1 (en) | 2011-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI1912673T1 (sl) | Postopek za povezovanje efektor molekul na proteine | |
| CO6180433A2 (es) | Moleculas de enlace de lingo y uso farmaceutico de las mismas | |
| IL190333A (en) | Process and intermediates for the synthesis of caspofungin | |
| MX338354B (es) | Nuevas amino carboxamidas azaheterociclicas. | |
| NZ597769A (en) | Proteins and nucleic acids from meningitis/sepsis-associated Escherichia Coli | |
| WO2007112940A3 (en) | Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same | |
| WO2007064917A3 (en) | Methods of preparation of recombinant forms of human beta-amyloid protein and uses of these proteins | |
| WO2009052396A3 (en) | Novel process for solubilizing protein from a proteinaceous material and compositions thereof | |
| MX2007011023A (es) | 2-(4-oxo-4h-quinazolin-3-il) acetamidas y su uso como antagonistas de vasopresin v3. | |
| EA201070510A1 (ru) | Система, образованная пневматической шиной и гибким органом | |
| TN2010000219A1 (en) | 5-[(3,3,3-trifluoro-2-hydroxy-1-arylpropyl)amino]-1h-quinolin-2-ones, a process for their production and their use as anti-inflammatory agents | |
| ATE496036T1 (de) | Zwischenprodukte für die herstellung von pramipexol | |
| NZ601142A (en) | Composition for improving brain function and method for improving brain function | |
| TW200740769A (en) | Novel process | |
| ATE517900T1 (de) | Heptarylen-und octarylentetracarbonsäurediimide und deren herstellung | |
| WO2006079057A3 (en) | Methods and compositions for specific inhibition of protein splicing by small molecules | |
| EA200700400A1 (ru) | Производные n-(1h-индолил)-1н-индол-2-карбоксамидов, их получение и их применение в терапии | |
| TW200633977A (en) | Novel process for the manufacture of 3-pyrrolidin-2-yl-propionic acid derivatives | |
| MY157846A (en) | Process for the purification of fc-containing proteins | |
| ATE461934T1 (de) | Verfahren zur herstellung von 17-hydroxy-6 beta, 7 beta, 15 beta,16 beta-bismethylen-17alpha-pregn-4-en-3-on-21-car onsäure -lacton und schlüsselzwischenprodukte für dieses verfahren | |
| TW200640911A (en) | Novel, long acting betamimetics for the treatment of respiratory diseases | |
| EA200701852A1 (ru) | Производные аминокислот | |
| ATE496941T1 (de) | Herstellung von insulinkonjugaten | |
| PT1819704E (pt) | Derivado amida de ácido pirrolopiridina-2-carboxílico útil como inibidor de glicogénio fosforilase | |
| TW200706951A (en) | Emireflective display and method thereof |